過剰栄養誘発性β細胞喪失に必要なPpid
Brittney A Covington1, Zihan Tang1, Lisette A Maddison1
1Department of Molecular Physiology and Biophysics, Vanderbilt University, Nashville, TN, USA.
American journal of physiology. Endocrinology and metabolism
|December 15, 2025
まとめ
シクロフィリンD(Ppid)は、2型糖尿病モデルにおけるβ細胞死を促進する。Ppidの阻害はβ細胞量を保護し、T2D治療の重要な標的を明らかにする。
科学分野:
- 内分泌学
- ミトコンドリア生物学
- 糖尿病研究
背景:
- 2型糖尿病(T2D)は、機能的β細胞量の進行性喪失を特徴とする。
- ゼブラフィッシュのインスリン抵抗性モデル(zMIR)における過剰栄養は、膵島炎症と夜間のβ細胞死を誘発する。
研究 の 目的:
- 過剰栄養誘発性インスリン抵抗性におけるβ細胞喪失の媒介におけるシクロフィリンD(Ppid)の役割を調査する。
- T2Dにおけるβ細胞量を維持するための治療標的を特定する。
主な方法:
- Ppidの遺伝子操作を用いたゼブラフィッシュインスリン抵抗性モデル(zMIR)を利用した。
- Ppid阻害剤シクロスポリンA(CsA)、ミトコンドリアROSスカベンジャーmito-TEMPO、およびミトコンドリアカルシウムキレーターRu360を投与した。
- β細胞量、膵島炎症、およびマクロファージ動員を評価した。
主要な成果:
- シクロスポリンA(CsA)は、zMIRにおける夜間のβ細胞死を防いだ。
- ミトコンドリア標的介入(mito-TEMPO、Ru360)はβ細胞を保護し、ミトコンドリア透過性遷移孔(mPTP)を関与させた。
- Ppidの全体的なノックアウトはβ細胞量を維持したが、β細胞特異的なPpid再発現はβ細胞喪失を回復および悪化させ、これはCsA感受性であった。
結論:
- Ppidは、過剰栄養誘発性β細胞喪失のβ細胞固有のメディエーターとして作用する。
- Ppidを標的とすることは、2型糖尿病におけるβ細胞機能を維持するための潜在的な治療戦略を提供する。
関連する概念動画
Cell Specific Gene Expression
16.2K
Multicellular organisms contain a variety of structurally and functionally distinct cell types, but the DNA in all the cells originated from the same parent cells. The differences in the cells can be attributed to the differential gene expression. Liver cells, whose functions include detoxification of blood, production of bile to metabolize fats, and synthesis of proteins essential for metabolism, must express a specific set of genes to perform their functions. Gene expression also varies with...
16.2K
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
2.1K
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
Insulin and C-peptide are...
2.1K
Carbohydrate Metabolism
13.7K
Carbohydrates are polymers composed of molecules containing atoms of carbon, hydrogen and oxygen. One gram of carbohydrate can provide four kilo-calories of energy, which makes it the most efficient instant energy source.
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
13.7K
Hypoglycemia and Glucagon
772
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
772
Insulin: Dosing Regimen and Adverse Effects
656
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
656
Glucagon-like Receptor Agonists
818
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
818


